The Road to BOFUSS: The Basic OpenFlow User-space Software Switch

Software switches are pivotal in the Software-Defined Networking (SDN) paradigm, particularly in the early phases of development, deployment and testing. Currently, the most popular one is Open vSwitch (OVS), leveraged in many production-based environments. However, due to its kernel-based nature, OVS is typically complex to modify when additional features or adaptation is required. To this regard, a simpler user-space is key to perform these modifications. In this article, we present a rich overview of BOFUSS, the basic OpenFlow user-space software switch. BOFUSS has been widely used in the research community for diverse reasons, but it lacked a proper reference document. For this purpose, we describe the switch, its history, architecture, uses cases and evaluation, together with a survey of works that leverage this switch. The main goal is to provide a comprehensive overview of the switch and its characteristics. Although the original BOFUSS is not expected to surpass the high performance of OVS, it is a useful complementary artifact that provides some OpenFlow features missing in OVS and it can be easily modified for extended functionality. Moreover, enhancements provided by the BEBA project brought the performance from BOFUSS close to OVS. In any case, this paper sheds light to researchers looking for the trade-offs between performance and customization of BOFUSS.Comment: 24 pages, 7 figures; submitted to Telecommunications Systems journa

A Single-Dose Influenza A (H5N1) Vaccine Safe and Immunogenic in Adult and Elderly Patients: an Approach to Pandemic Vaccine Development▿

With the ongoing pandemic of influenza A (H1N1) virus infection and the threat of high fatality rates for recent human cases of infection with highly pathogenic H5N1 strains, there has been considerable interest in developing pandemic vaccines. Here we report a randomized multicenter dose-finding clinical trial of a whole-virion, inactivated, adjuvanted H5N1 vaccine in adult and elderly volunteers. Four hundred eighty patients were randomly assigned to receive one or two doses of 3.5 μg of the vaccine or one dose of 6 or 12 μg. The subjects were monitored for safety analysis, and serum samples were obtained to assess immunogenicity by hemagglutination inhibition and microneutralization tests. The subjects developed antibody responses against the influenza A (H5N1) virus. Single doses of ≥6 μg fulfilled EU and U.S. licensing criteria for interpandemic and pandemic influenza vaccines. Except for occasional injection site pain, malaise, and fever, no adverse events were observed. We found that the present vaccine is safe and immunogenic in healthy adult and elderly subjects and requires low doses and, unlike any other H5N1 vaccines, only one injection to trigger immune responses which comply with licensing criteria. A vaccine using the same methods as those described in this report, but based on a wild-type swine-origin 2009 (H1N1) influenza A virus isolate from the United States (supplied by the CDC), has been developed and is currently being tested by our group